SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
... psoriatic arthritis (PsA) and severe, active
ankylosing spondylitis (AS).
Upon Commission approval ... of rheumatoid arthritis, psoriatic arthritis and
ankylosing spondylitis in the European Union," said Jerome ... the peak of their productive years.
About
ankylosing Spondylitis ...
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
... in patients with psoriatic arthritis (PsA) and
ankylosing spondylitis (AS). Investigators reported these ... at two years. Improvements in the Assessment in
ankylosing Spondylitis criteria (ASAS 20) were maintained ... living with the chronic inflammatory disease,
ankylosing spondylitis," said Jurgen Braun, MD, lead ...
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
... for the treatment of RA,
psoriatic arthritis and
ankylosing spondylitis.
In the study, GOlimumab FOR ... for adults with RA, psoriatic
arthritis and
ankylosing spondylitis. The initial submission and Phase ... for the treatment of
RA, psoriatic arthritis and
ankylosing spondylitis, golimumab is being
studied as an ...
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
... improvements in the signs and
symptoms of active
ankylosing spondylitis, according to Phase 3 study
results ... through six months as measured
by the Bath
ankylosing Spondylitis Functional Index (BASFI). Golimumab, ... ASAS 40, defined as 40 percent
improvement in
ankylosing spondylitis signs and symptoms, compared with ...
CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
... patients with polyarticular
symmetrical subtypes of the disease.
ankylosing spondylitis
Treatment of adults with severe active
ankylosing spondylitis who have
had an inadequate response to conventional therapy.
...
New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study
... People who have been treated for rheumatoid
arthritis, Crohn's disease,
ankylosing spondylitis, psoriatic arthritis or
plaque psoriasis for a long time, ... innovation to the treatment
of Crohn's disease, rheumatoid arthritis,
ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis, pediatric Crohn's ...
New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
... People who have been treated for rheumatoid
arthritis, Crohn's disease,
ankylosing spondylitis, psoriatic arthritis or
plaque psoriasis for a long time, ... innovation to the treatment
of Crohn's disease, rheumatoid arthritis,
ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis, pediatric Crohn's ...
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
... People who have been treated for rheumatoid
arthritis, Crohn's disease,
ankylosing spondylitis, psoriatic arthritis, or
plaque psoriasis for a long time, ... innovation to the treatment
of Crohn's disease, rheumatoid arthritis,
ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis, pediatric Crohn's ...
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
... to severe rheumatoid arthritis in 2002, psoriatic
arthritis in 2005,
ankylosing spondylitis in 2006, and moderate to severe
Crohn's disease in 2007.
... considered before initiating therapy.
In HUMIRA clinical trials for
ankylosing spondylitis, psoriatic
arthritis, Crohn's disease and plaque psoriasis, ...
Abbott's m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
... is also approved for reducing signs and
symptoms in patients with active
ankylosing spondylitis. Earlier this year, HUMIRA was approved for reducing the ... considered
before initiating therapy. In HUMIRA clinical trials for
ankylosing spondylitis, psoriatic
arthritis and Crohn's disease, the safety profile ...
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
... arthritis in adults, in combination with methotrexate; active psoriatic arthritis in adults, alone or in combination with methotrexate; and active
ankylosing spondylitis in adults.
Indications in Canada:
In Canada, SIMPONI, in combination with methotrexate (MTX), is indicated for reducing the ...
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
... rheumatology and dermatology. REMICADE has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA),
ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy ...
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
... (golimumab), a once-monthly subcutaneous anti-TNF agent for inflammatory and autoimmune disorders (under review in EU for rheumatoid arthritis,
ankylosing spondylitis and psoriatic arthritis, and in Phase III for ulcerative colitis); Schering-Plough has exclusive marketing rights to golimumab outside ...
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
... HUMIRA is the only fully human monoclonal antibody approved for the
treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA),
psoriasis,
ankylosing spondylitis (AS), Crohn's disease and juvenile
idiopathic arthritis (JIA) in the United States and Europe. HUMIRA
resembles antibodies normally found ...
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
... biomedicines that transform
patients' lives. Centocor has already brought innovation to the treatment
of Crohn's disease, rheumatoid arthritis,
ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.
The world leader in monoclonal antibody production ...
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
... percent vs. 9 percent). Discontinuations due to
adverse events were 7 percent for HUMIRA and 4 percent for placebo.
In HUMIRA clinical trials for
ankylosing spondylitis, psoriatic
arthritis, Crohn's disease and plaque psoriasis, the safety profile for
adult patients treated with HUMIRA was similar to the ...
Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis
... biomedicines that transform
patients' lives. Centocor has already brought innovation to the treatment
of Crohn's disease, rheumatoid arthritis,
ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.
The world leader in monoclonal antibody production ...
Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
... owned subsidiary of Amgen, manufactures ENBREL, which
may be used to treat rheumatoid arthritis, junior rheumatoid arthritis,
psoriatic arthritis,
ankylosing spondylitis and psoriasis. Additional
information about ENBREL, including the full U.S. Prescribing Information,
can be found on the Web site ...
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
... biomedicines that transform
patients' lives. Centocor has already brought innovation to the treatment
of Crohn's disease, rheumatoid arthritis,
ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.
The world leader in monoclonal antibody production ...
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
... biomedicines that transform
patients' lives. Centocor has already brought innovation to the treatment
of Crohn's disease, rheumatoid arthritis,
ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. The world leader in monoclonal antibody production ...
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
... biomedicines that transform
patients' lives. Centocor has already brought innovation to the treatment
of Crohn's disease, rheumatoid arthritis,
ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. The world leader in monoclonal antibody production ...
Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
... biomedicines that transform
patients' lives. Centocor has already brought innovation to the treatment
of Crohn's disease, rheumatoid arthritis,
ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. The world leader in monoclonal antibody production ...
New Analysis of Data Shows Treatment With Abbott's Humira
(Adalimumab) Significantly Reduced Disease-Related Hospitalization
for Patients with Crohn's Disease
... therapy.
In HUMIRA clinical trials for
ankylosing spondylitis, psoriatic
arthritis and Crohn's ... arthritis (RA), psoriatic arthritis
(PsA) and
ankylosing spondylitis (AS, an arthritis of the spine) ... signs and symptoms in patients with
active
ankylosing spondylitis. HUMIRA is also indicated ...
Remicade Two Year Data in Ankylosing Spondylitis Show Improvement
in Spinal Mobility and Spinal Inflammation
... from 279 patients with AS
as part of the
ankylosing Spondylitis Study for the Evaluation ... placebo-controlled study
utilized the Bath
ankylosing Spondylitis Metrology Index (BASMI)
and chest ... see "Important Safety Information" below.
About
ankylosing Spondylitis
AS is a painful and progressive ...
Long-Term Extension of Ulcerative Colitis Study Shows Remicade
Responders Maintained Improvement Through Two Years of Follow-Up
... broad clinical utility in Crohn's disease (CD),
rheumatoid arthritis (RA),
ankylosing spondylitis (AS), psoriatic
arthritis (PsA), ulcerative colitis (UC), ... People who have been treated for
rheumatoid arthritis, Crohn's disease,
ankylosing spondylitis,
psoriatic arthritis, or plaque psoriasis for a long ...
Enbrel Safety Data for up to Eight Years in Patients with Juvenile
Rheumatoid Arthritis Being Presented at EULAR
... is indicated for reducing signs and symptoms in
patients with active
ankylosing spondylitis.
-- ENBREL is indicated for the treatment of adult patients ... called TNF. People with an immune disease, such as
rheumatoid arthritis,
ankylosing spondylitis, psoriatic arthritis,
and psoriasis, have too much TNF in ...
Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data
Published in JAMA
... and in a number of over-the-counter medications. Naproxen
sodium is indicated for the treatment of rheumatoid arthritis,
osteoarthritis,
ankylosing spondylitis and juvenile arthritis. It
is also indicated for the treatment of tendonitis, bursitis, acute
gout and for the management of pain and ...
Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across
Multiple Migraine Attacks
... and in a number of over-the-counter medications. Naproxen
sodium is indicated for the treatment of rheumatoid arthritis,
osteoarthritis,
ankylosing spondylitis and juvenile arthritis. It
is also indicated for the treatment of tendinitis, bursitis, acute
gout and for the management of pain and ...
Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both
Traditional and Non-traditional Migraine Symptoms
... and in a number of over-the-counter medications. Naproxen
sodium is indicated for the treatment of rheumatoid arthritis,
osteoarthritis,
ankylosing spondylitis and juvenile arthritis. It
is also indicated for the treatment of tendinitis, bursitis, acute
gout and for the management of pain and ...
Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free
Response Across Multiple Attacks
... and in a number of over-the-counter medications. Naproxen
sodium is indicated for the treatment of rheumatoid arthritis,
osteoarthritis,
ankylosing spondylitis and juvenile arthritis. It
is also indicated for the treatment of tendinitis, bursitis, acute
gout and for the management of pain and ...
Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work
Productivity in Patients with Rheumatoid Arthritis
... About HUMIRA
HUMIRA is the only fully human monoclonal antibody approved for
the treatment of rheumatoid arthritis (RA), psoriatic arthritis
(PsA),
ankylosing spondylitis (AS, an arthritis of the spine) and
Crohn's disease in the U.S. and Europe. HUMIRA resembles antibodies
normally found in the body. It ...